A bioequivalence study of two levofloxacin tablets in healthy male subjects

Inbum Chung¹, Seonghae Yoon¹, SoJeong Yi¹, Bo-Hyung Kim³, Sung-Vin Yim³, In-Jin Jang¹ and Howard Lee¹,²,*
¹Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital and College of Medicine, Seoul 110-744, Korea, ²Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 110-744, Korea, ³Department of Clinical Pharmacology and Therapeutics, Kyung Hee University College of Medicine and Hospital, Seoul 130-872, Korea
*Correspondence: H. Lee; Tel: +82-2-3668-7602, Fax: +82-2-2072-4081, E-mail: howardlee@snu.ac.kr, leehwd@gmail.com

Levofloxacin is a bactericidal broad spectrum antibiotic against Gram-positive and Gram-negative pathogens. A randomized, two-treatment, two-period, two-way crossover study was conducted to evaluate the bioequivalence of Lectacin 250 mg tablet, a generic levofloxacin, to its reference drug, Cravit 250 mg tablet. Each period was separated by a 7-day washout. Serial blood samples were collected until 24 h after dosing and plasma levofloxacin concentrations were determined using a high performance liquid chromatography. Pharmacokinetic parameters were analyzed using K-BE Test 2007 and BA calc 2007 (Ministry of Food and Drug Safety, Cheongju-si, South Korea). The peak concentration (C_{\text{max}}) and the area under the plasma concentration versus time curve from 0 to the last measurable concentration (AUC_{0-t}) for the generic and reference levofloxacin were 4.48±0.89 mg/L and 4.46±0.95 mg/L, and 25.33±4.12 mg*h/L and 25.77±4.01 mg*h/L, respectively, leading to a geometric mean ratio (90% confidence interval) of the generic to the reference levofloxacin of 1.0060 (0.9339-1.0842) and 0.9810 (0.9476-1.0159), respectively, for C_{\text{max}} and AUC_{0-t}. Lectacin 250 mg tablet is bioequivalent to Cravit 250 mg tablet.

Introduction

Levofloxacin is the active S-enantiomer (L-isomer) of the racemic drug ofloxacin, an oral fluoroquinolone antimicrobial agent, and is approximately two times as potent as ofloxacin.[1] Levofloxacin possesses a broad spectrum of bactericidal activity against Gram-positive and Gram-negative pathogens such as Chlamydia, Legionella and Mycobacterium, which has made levofloxacin effective for the treatment of infectious diseases such as community-acquired pneumonia and acute exacerbation of chronic bronchitis.[2-5]

In South Korea, levofloxacin has been approved to treat uncomplicated or complicated urinary tract infection, chronic bacterial prostatitis, community-acquired pneumonia, nosocomial pneumonia, and skin and/or subcutaneous tissue infections. For these indications, a daily dose of levofloxacin between 250 mg and 750 mg can be used. Among the dose strengths approved in South Korea, 250 mg is the most frequently used one given the dosage recommendations.

UNIMED Pharm Inc. (Seoul, South Korea) has developed a new formulation of levofloxacin, Lectacin 250 mg tablet, containing the same amount of active ingredient and excipients as the reference levofloxacin drug, Cravit 250 mg tablet (Jeil Pharmaceutical Co. Ltd., Seoul, South Korea), which was approved by the Ministry of Food and Drug Safety (MFDS) for the indications mentioned above.

The aim of the present study was to compare the pharmacokinetic profile of Lectacin 250 mg tablet (test drug) with that of Cravit 250 mg tablet (reference drug) and to assess the bioequivalence of the two formulations.

Methods

This study was conducted at the Clinical Trials Center (CTC), Kyung Hee University Hospital (KHUH), Seoul, South Korea. The protocol was approved by the institutional review board at KHUH. Participants voluntarily provided written informed consent as per the Declaration of Helsinki of 1975 (as revised in 2000 and 2013) and the Good Clinical Practice guidelines.
consent before any screening test or procedure for eligibility was performed.

Study products
The test and reference drugs were Lectacin 250 mg tablet (batch number 08001, manufacture by UNIMED Pharm Inc., South Korea) and Cravit 250 mg tablet (batch number CRHB02, manufactured by Jeil Pharmaceutical Co., Ltd. in South Korea), respectively.

Study volunteers
Healthy Korean male volunteers aged 19 to 55 years were enrolled into this study. Eligible volunteers had to present no abnormalities based on screening, physical examination, vital signs, and routine clinical laboratory tests (hematology, clinical chemistry, and urinalysis). Volunteers were excluded if they had a history of hepatic, renal, pulmonary, cardiac, gastrointestinal, neurologic, or hematologic disorders. Eligible volunteers were instructed to abstain from taking alcohol, cigarette, and any drug for at least 72 hours prior to and during the study period. The study was conducted in accordance with the bioequivalence study guidelines published by the Ministry of Food and Drug Safety (MFDS) in South Korea.[6]

Study design
The study was conducted as a single dose, randomized, two-treatment, two-period, two-sequence, crossover design. Each period was separated by a 1-week washout, which was more than five times the half-life of levofloxacin.[5,7] A total of 26 volunteers were randomized into 2 sequences (A: test to reference, B: reference to test). After an overnight fasting of at least 12 hours, all volunteers were given a single oral dose of a test or reference levofloxacin with 240 mL of water in the morning on day 1 and 8 according the randomized sequence. Regular standardized meals were provided 4 hour after dose administration. Dietary, smoking, and drug-herbal product restrictions were maintained throughout the study period.

Pharmacokinetic samples collection
Blood samples (7 mL each) were drawn at 0 (i.e., pre-dose), 0.33, 0.67, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours after drug administration. A heparin-locked catheter was placed into the volunteer’s forearm vein before drug administration and was left in place until the 24 hour blood sample was collected. Collected blood samples were centrifuged at 1,811 g for 10 minutes. The plasma was decanted in coded polypropylene tubes and stored at -70°C until analysis.

Quantification of levofloxacin concentration in plasma
Plasma concentrations of levofloxacin were determined by a validated method using high performance liquid chromatography (HPLC, Agilent 1200 series, Agilent Technologies, Santa Clara, CA, USA) coupled with tandem mass spectrometry (MS/MS, API3200, Applied Biosystems/MDS SCIEX, Foster City, CA, USA). A Luna 3u column (100 x 2.0 mm, Phenomenex, Torrance, CA, USA) was used with gradient mobile phase consisting of acetonitrile: 0.2% formic acid (50:50 v/v) and a flow rate of 0.3 mL/min. One hundred μL of plasma was added to 900 μL of enoxacin (internal standard, 1 μg/mL). After agitation for 30 second, the samples were centrifuged at 12,000 rpm for 8 minutes, and 1 μL of supernatant was injected into the HPLC system for analysis. The lower limit of quantification for levofloxacin was 0.1 μg/mL and the calibration curve was linear over the concentration range of 0.1-10 μg/mL with a mean correlation coefficient of 0.9972. The intra-batch and inter-batch accuracy was 87.22-101.66% and 87.22-101.66%, respectively, over the entire range of the calibration curve using known levofloxacin concentrations (Table 1), indicating that the bioanalytical method was accurate. Likewise, the intra-batch and inter-batch coefficient of variation ranged from 1.707 to 3.436% and from 2.865 to 7.587%, respectively, indicating that the method was precise.

Table 1. Accuracy and precision of levofloxacin concentration measurement by LC-MS/MS method (n=5)

<table>
<thead>
<tr>
<th>Concentration (μg/mL)</th>
<th>Accuracy (%)</th>
<th>Precision (% Coefficient of Variance)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intra-batch (n=5)</td>
<td>Intra-batch (n=5)</td>
</tr>
<tr>
<td>0.1</td>
<td>87.22</td>
<td>3.335</td>
</tr>
<tr>
<td>0.25</td>
<td>101.66</td>
<td>3.436</td>
</tr>
<tr>
<td>5</td>
<td>100.48</td>
<td>3.379</td>
</tr>
<tr>
<td>10</td>
<td>96.14</td>
<td>1.707</td>
</tr>
</tbody>
</table>

Pharmacokinetic analysis
The peak plasma concentration (Cmax) and the time to Cmax (tmax) were taken directly from the observed values. The pharmacokinetic parameters were calculated and compared using K-BE Test 2007 ver 1.1.0 and BA calc 2007 ver 1.0.0 (MFDS, Seoul, South Korea, both software programs). The area under the plasma concentration versus time curve from 0 to the last measurable concentration (AUC0-t) was calculated with the linear trapezoidal rule.

Statistical analysis
Statistical analysis was performed using K-BE Test 2007 ver 1.1.0 (MFDS, Seoul, South Korea) or SPSS® (SPSS Korea, Seoul, South Korea). Descriptive statistics were used to summarize baseline demographics such as age, height, and body weight, and PK parameters. The geometric mean ratio (GMR) and its 90% confidence interval (CI) of the test to reference formulas of levofloxacin were estimated for Cmax and AUC0-t using a linear mixed-effect model, in which natural logarithm-transformed Cmax and AUC0-t were the dependent variables.
treatment, sequence, and period were fixed effects, and subject nested for sequence was random effect. The two formulation were considered bioequivalent if the 90% confidence intervals for GMR fell entirely within the range of 0.80-1.25.

Results

Subjects
Twenty six healthy Korean adult male volunteers were enrolled and there was no dropout during the study. All the volunteers completed the study according to the study protocol and were included in the PK and safety analysis populations. The demographic characteristics of the volunteers are presented in Table 2.

Pharmacokinetics
The mean plasma concentration-time profiles of levofloxacin after a single oral administration of the two formulations were almost superimposable (Fig. 1). Both levofloxacin formulations were rapidly absorbed (\( t_{\text{max}} \): 0.33 - 2.5 h, Table 3), and they were eliminated mono-exponentially (Fig. 1). \( C_{\text{max}} \) and AUC\(_{0-t}\) of levofloxacin was similar between the two formulations (Table 3), leading to a geometric mean ratio of 0.981 and 1.006, respectively. The 90% confidence interval for GMR of \( C_{\text{max}} \) and AUC\(_{0-t}\) were [0.9339-1.0842] and [0.9476-1.0159], respectively, falling entirely within the conventional bioequivalence range of [0.8-1.25], which also included unity (Table 3).

Tolerability evaluation
Both levofloxacin formulations were well tolerated by all the volunteers. There was no unexpected adverse event. None of the changes in laboratory tests and vital signs during the study were considered clinically important.

Discussion
The present study showed that the two formulations of levofloxacin (i.e., Lectacin 250 mg tablet and Cravit 250 mg tablet)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Test (n=26)</th>
<th>Reference (n=26)</th>
<th>Geometric mean ratio (90% confidence interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>( t_{\text{max}} ) (h)</td>
<td>1.0 (0.33–2.5)</td>
<td>0.84 (0.67–2.5)</td>
<td></td>
</tr>
<tr>
<td>( C_{\text{max}} ) (μg/mL)</td>
<td>4.48±0.89 [4.39]</td>
<td>4.46±0.95 [4.36]</td>
<td>1.0060 (0.9339–1.0842)</td>
</tr>
<tr>
<td>AUC(_{0-t}) (h·μg/mL)</td>
<td>25.33±4.12 [24.99]</td>
<td>25.77±4.01 [25.47]</td>
<td>0.9810 (0.9476–1.0159)</td>
</tr>
<tr>
<td>( t_{1/2} ) (h)</td>
<td>6.5±0.8</td>
<td>6.7±0.8</td>
<td></td>
</tr>
<tr>
<td>CL/F (mL/h)</td>
<td>9328.5±1552.3</td>
<td>9011.2±1369.5</td>
<td></td>
</tr>
</tbody>
</table>

All values are presented as mean±SD [geometric mean], except for \( t_{\text{max}} \) for which median (range) is presented. AUC\(_{0-t}\) = area under the plasma concentration-time curve (AUC) from time 0 to 24 hours post dose; \( C_{\text{max}} \) = peak plasma drug concentration; \( t_{\text{max}} \) = time to reach peak plasma concentration; Test = Lectacin 250 mg tablet; Reference = Cravit 250 mg tablet
are bioequivalent. Evidence is that the point estimate of the GMR of the test to the reference was close to unity (i.e., 1) for both the peak concentration and the area under the concentration-time curve, and its 90% confidence interval was contained entirely within the conventional bioequivalence range of [0.8-1.25] (Table 3), which has been also used by MFDS as the regulatory standard for approving the generic formulation.[6] Furthermore, other pharmacokinetics parameters including half-life ($t_{1/2}$) and apparent clearance were also similar to each other (Table 3), resulting in the almost overlapping concentration-time profiles between the reference and test formulations of levofloxacin. Moreover, the two formulations of levofloxacin were well tolerated. Because the pharmacokinetics of levofloxacin is linear over the dose range in the approved regimens,[8] the test formulation of levofloxacin can be also effectively used for daily doses of multiples of 250 mg.

Levofloxacin was rapidly absorbed after a single oral administration. In this study, the time to peak concentration ($t_{\text{max}}$) ranged between 0.33 and 2.5 h, which was consistent with not only what has been reported previously,[7,9] but the one in the drug label.[8] Orally administered levofloxacin is almost completely absorbed as indicated by its high bioavailability of ~99%. [5,8] Therefore, the low inter- and intra-individual variability in the exposure to levofloxacin, which has been also shown in the present study (i.e., <17%, Table 3), could be also due to its high bioavailability. Likewise, the half-life of levofloxacin was ~6.5 h (Table 3), which was in full agreement with the previously reported values of 6 to 8 h following a single or multiple oral doses.[1,5,9,10] Thus, one week was sufficient and appropriate as wash-out as employed in the present study.

In conclusion, the test formulation of levofloxacin (Lectacin 250 mg tablet) is bioequivalent to the reference formulation (Cravit 250 mg tablet). The two formulations of levofloxacin were well tolerated.

Acknowledgments
This study was supported by a research grant from UNIMED Pharm Inc. (Seoul, South Korea).

Conflict of Interest
All authors have nothing to declare.

References